» Articles » PMID: 39712283

Reduced Ovarian Function in Women with Complex Congenital Heart Disease

Overview
Date 2024 Dec 23
PMID 39712283
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There is a high prevalence of menstrual disturbance in women with congenital heart disease (CHD). The purpose of this study was to evaluate ovarian function in women with CHD and factors associated with ovarian function.

Design: Sixty-one women with more than moderate complexity of CHD who visited our hospital from March to December in 2019 were prospectively enrolled. We investigated menstrual bleeding patterns with a questionnaire. Serum anti-Müllerian hormone (AMH) levels, which reflect ovarian reserve, were measured in 43 women (28.1±8.7 years old) with CHD and 43 age-matched healthy women controls. Ratios of AMH levels to the median of reference values (provided by Beckman Coulter, Inc.) at each age were expressed as percentages (%AMH). The %AMH were evaluated for each clinical characteristic (oxygen saturation, NYHA class, Fontan circulation, cardiac complexity, physiological stage).

Results: Menstrual cycle disorders were observed in 29 of 43 patients (68%) with CHD. The most frequent menstrual cycle disorder was frequent menstrual bleeding, observed in 14 patients (32%). Serum AMH levels were significantly lower in women with CHD than in controls (2.66±2.10 vs 4.55±4.02 ng/mL, P=0.008). The %AMH in women with Fontan circulation was significantly decreased, compared with those of controls [56.7 (1.1-152.4) % vs 94.6 (24.2-396.6) % P= 0.003]. The %AMH significantly reduced even in women with CHD whose oxygen saturation did not reduce (≧96%) [58.6 (4.9-313.9) % vs 94.6 (24.2-396.6) % P=0.033].

Conclusion: Measurements of AMH revealed reduced ovarian function that contributed to menstrual cycle disorders in patients with CHD.

References
1.
Ferraretti A, La Marca A, Fauser B, Tarlatzis B, Nargund G, Gianaroli L . ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011; 26(7):1616-24. DOI: 10.1093/humrep/der092. View

2.
Dewailly D, Andersen C, Balen A, Broekmans F, Dilaver N, Fanchin R . The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update. 2014; 20(3):370-85. DOI: 10.1093/humupd/dmt062. View

3.
Stout K, Daniels C, Aboulhosn J, Bozkurt B, Broberg C, Colman J . 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018; 139(14):e637-e697. DOI: 10.1161/CIR.0000000000000602. View

4.
Khajali Z, Ziaei S, Maleki M . Menstrual Disturbances in Women With Congenital Heart Diseases. Res Cardiovasc Med. 2016; 5(3):e32512. PMC: 5075427. DOI: 10.5812/cardiovascmed.32512. View

5.
Houston A, Abraham A, Huang Z, DAngelo L . Knowledge, attitudes, and consequences of menstrual health in urban adolescent females. J Pediatr Adolesc Gynecol. 2006; 19(4):271-5. DOI: 10.1016/j.jpag.2006.05.002. View